Andrew Ball

Andrew Ball is currently the Chief Executive Officer at SeromYx Systems, Inc., where they focus on correlating antibody effector function to product efficacy. Previously, they held various leadership roles, including Vice President at Abcam and Quad Technologies, where they led research and development efforts in cell therapy and assay development. Andrew's academic background includes a Ph.D. in Cell Biology and Pharmacology from the University of Ulster, complemented by a postdoctoral fellowship at multiple prestigious institutions, where they developed novel assays for biomedical research. Their extensive experience spans over two decades in the life sciences sector, contributing significantly to innovations in bioprocessing and therapeutic development.